References
Cornish-Bowden A. A simple graphical method for determining the inhibition constants
of mixed, uncompetitive and non-competitive inhibitors. Biochemistry J 1974;
137:143–144.
Cornish-Bowden A. Fundamentals of Enzyme Kinetics. London: Portland Press; 2004.
Dabrowski MJ, Schrag ML, Wienkers LC, Atkins WM. Pyrene.pyrene complexes at the
active site of cytochrome P450 3A4: evidence for a multiple substrate binding site.
J Am Chem Soc 2002;124:11866–11867.
Dixon M. The determination of enzyme inhibitor constants. Biochemistry 1953;55:
170–171.
Dowd JE, Riggs DS. A comparison of estimates of Michaelis–Menten kinetic constants
from various linear transformations. J Biol Chem 1965;240:863–869.
Egnell AC, Houston JB, Boyer CS.In vivoCYP3A4 heteroactivation is a possible
mechanism for the drug interaction between felbamate and carbamazepine.
J Pharmacol Exp Ther 2003;305:1251–1262.
Houston JB. Utility ofin vitrodrug metabolism data in predictingin vivometabolic
clearance. Biochem Pharmacol 1994;47:1469–1479.
Hummel MA, Gannett PM, Aguilar JS, Tracy TS. Effector-mediated alteration of
substrate orientation in cytochrome P450 2C9. Biochemistry 2004;43:7207–7214.
Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated
metabolism: evidence for activation of multiple substrates and a two-site model.
Drug Metab Dispos 2001;29:1029–1034.
Hutzler JM, Tracy TS. Atypical kinetic profiles in drug metabolism reactions. Drug
Metab Dispos 2002;30:355–362.
Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, Tracy TS. Activation of
cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of
kinetic observations. Arch Biochem Biophys 2003;410:16–24.
Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3
A4:simultaneous activation and inhibition of diazepam and testosterone metabolism.
Drug Metab Dispos 2001;29:1644–1651.
Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez
FJ, Tracy TS. Evaluation of atypical cytochrome P450 kinetics with two-substrate
models: evidence that multiple substrates can simultaneously bind to cytochrome
P450 active sites. Biochemistry 1998;37:4137–4147.
Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M.
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab
Dispos 2001;29:368–374.
Pfeiffer E, Treiling CR, Hoehle SI, Metzler M. Isoflavones modulate the glucuronida-
tion of estradiol in human liver microsomes. Carcinogenesis 2005;26:2172–2178.
Rock DA, Perkins BN, Wahlstrom J, Jones JP. A method for determining two
substrates binding in the same active site of cytochrome P450B M3: an explanation
of high energy omega product formation. Arch Biochem Biophys 2003;416:9–16.
Segel IH. Rapid Equilibrium Bireactant and Terreactant Systems. New York: John
Wiley & Sons, Inc.; 1975.
REFERENCES 111